Related Experiment Video
Updated: Jul 9, 2025
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Lipid metabolism drives allele-specific early-stage hypertrophic cardiomyopathy
Insights
Hypertrophic cardiomyopathy (HCM) involves genetic variants affecting heart muscle energy. This study reveals distinct metabolic changes and mitochondrial dysfunction in early-stage HCM mouse models, impacting cardiac function.
Area of Science:
- Cardiovascular biology
- Metabolomics
- Mitochondrial function
Background:
- Hypertrophic cardiomyopathy (HCM) stems from genetic mutations in sarcomeric proteins, elevating myocyte energy demands and causing cardiac hypertrophy.
- The presence of a common metabolic trait underlying early-stage cardiac phenotypes in HCM remains unclear.
Approach:
- Characterized two distinct HCM mouse models (R92W-TnT and R403Q-MyHC) exhibiting differential mitochondrial function.
- Employed a multidisciplinary approach including cardiac phenotyping, transcriptomics, mass spectrometry-based metabolomics, and computational modeling.
- Analyzed allele-specific variations in cardiac structure, function, and metabolic profiles.
Key Points:
- TnT-mutant hearts displayed impaired energy substrate metabolism and heightened phospholipid remodeling compared to MyHC-mutants.
- TnT-mutants exhibited increased saturated fatty acid incorporation into ceramides and cardiolipin.
- Elevated lipid peroxidation was observed in TnT-mutants, potentially explaining allele-specific mitochondrial dysfunction.
Conclusions:
- HCM pathogenesis involves allele-specific metabolic alterations and mitochondrial dysfunction.
- Metabolic remodeling, particularly lipid metabolism and peroxidation, plays a crucial role in HCM development.
- These findings offer insights into the molecular mechanisms driving HCM and potential therapeutic targets.
Abstract:
Hypertrophic cardiomyopathy (HCM) results from pathogenic variants in sarcomeric protein genes, that increase myocyte energy demand and lead to cardiac hypertrophy. But it is unknown whether a common metabolic trait underlies the cardiac phenotype at early disease stage. This study characterized two HCM mouse models (R92W-TnT, R403Q-MyHC) that demonstrate differences in mitochondrial function at early disease stage. Using a combination of cardiac phenotyping, transcriptomics, mass spectrometry-based metabolomics and computational modeling, we discovered allele-specific differences in cardiac structure/function and metabolic changes. TnT-mutant hearts had impaired energy substrate metabolism and increased phospholipid remodeling compared to MyHC-mutants. TnT-mutants showed increased incorporation of saturated fatty acid residues into ceramides, cardiolipin, and increased lipid peroxidation, that could underlie allele-specific differences in mitochondrial function and cardiomyopathy.
